Cardiac Medicine Certification (CMC) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Prepare for your Cardiac Medicine Certification (CMC) Test with comprehensive quizzes, case studies, and helpful materials. Enhance your knowledge and gain confidence before the big day!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

What is the antiplatelet medication commonly used after a NSTEMI to prevent reocclusion of stents?

Warfarin
Aspirin
Clopidogrel (Plavix)
Beta-blockers

The correct answer is: Clopidogrel (Plavix)

In the context of managing patients following a Non-ST-Elevation Myocardial Infarction (NSTEMI) and the placement of a stent, Clopidogrel (Plavix) plays a crucial role in preventing stent reocclusion. Following the acute event, antiplatelet therapy is essential to inhibit the activation and aggregation of platelets, which can lead to the formation of thrombus (clots) at the site of the stent and result in blockage. Clopidogrel is a thienopyridine that works by irreversibly inhibiting the P2Y12 receptor on platelets, which is critical for platelet activation and aggregation. When combined with aspirin, which inhibits the cyclooxygenase (COX) enzyme and decreases thromboxane A2 production, this dual antiplatelet therapy significantly enhances protection against thrombus formation after stent placement. While aspirin also serves as an important component of post-stenting therapy, it is the specific role of Clopidogrel in directly preventing platelet activation and thus reocclusion that makes it particularly significant in this scenario, especially when considering clopidogrel's synergistic effect with aspirin. Other options, such as warfarin and beta-block